Interstitial lung disease associated with anti-PM-Scl antibody: A single center experience.

[1]  V. Cottin,et al.  Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. , 2019, Autoimmunity reviews.

[2]  E. Savarino,et al.  Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. , 2016, Autoimmunity reviews.

[3]  A. Guillén-del Castillo,et al.  Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM/Scl antibody. , 2014, Seminars in arthritis and rheumatism.

[4]  V. Cottin,et al.  The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. , 2014, Autoimmunity reviews.

[5]  P. V. van Riel,et al.  Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology , 2014, Arthritis Research & Therapy.

[6]  V. Cottin,et al.  Interstitial Lung Disease Associated with Anti-PM/Scl or Anti-Aminoacyl-tRNA Synthetase Autoantibodies: A Similar Condition? , 2010, The Journal of Rheumatology.

[7]  L. Mouthon,et al.  Long‐term outcome of patients with polymyositis/ dermatomyositis and anti‐PM‐Scl antibody , 2010, The British journal of dermatology.

[8]  Reinout Raijmakers,et al.  Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights. , 2007, Autoimmunity reviews.

[9]  A. Selva-O'Callaghan,et al.  Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy. , 2006, Arthritis and rheumatism.

[10]  J. Sibilia,et al.  Anti-pm/scl antibodies in connective tissue disease: Clinical and biological assessment of 14 patients. , 2006, Clinical and experimental rheumatology.

[11]  T. Bunch,et al.  Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes , 2004, Journal of Clinical Immunology.

[12]  J. Reveille,et al.  The clinical relevance of autoantibodies in scleroderma , 2003, Arthritis research & therapy.

[13]  S. Jablonska,et al.  Scleroderma overlap syndromes. , 1999, Advances in experimental medicine and biology.

[14]  I. Hausmanowa-Petrusewicz,et al.  Clinical, serologic, and immunogenetic features in Polish patients with idiopathic inflammatory myopathies. , 1997, Arthritis and rheumatism.

[15]  M. Walport,et al.  The Clinical and Immunogenetic Features of Patients with Autoantibodies to the Nucleolar Antigen PM-Scl , 1992, Medicine.

[16]  M. Trucco,et al.  Serum autoantibody to the nucleolar antigen PM-Scl. Clinical and immunogenetic associations. , 1992, Arthritis and rheumatism.

[17]  M. Meurer,et al.  Immunogenetic associations of scleroderma-related antinuclear antibodies. , 1990, Arthritis and rheumatism.

[18]  G. Reimer,et al.  Immunolocalization and partial characterization of a nucleolar autoantigen (PM-Scl) associated with polymyositis/scleroderma overlap syndromes. , 1986, Journal of immunology.

[19]  J. F. Wolfe,et al.  Antinuclear antibody with distinct specificity for polymyositis. , 1977, The Journal of clinical investigation.